Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells (Sumitomo Dainippon Pharma)
N/A
Report date: 2022/01/14 13:23:58
Base Information
Drug NameAllogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells (Sumitomo Dainippon Pharma)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSumitomo Dainippon
China Registration ClassN/A
Develop Information
Other Information
ATC CodeN/A
Related LinksN/A